|
A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers
|
March 4, 2022
|
PC3I Authors Charu Aggarwal |
Oral Oncology
|
|
Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC-Results From a Prospective Pilot Study
|
April 8, 2022
|
PC3I Authors Charu Aggarwal; Melina Marmarelis; Christopher A. D’Avella; Anil Vachani |
JTO Clinical and Research Reports
|
|
Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed
|
April 8, 2022
|
PC3I Authors Charu Aggarwal; Melina Marmarelis; Christopher A. D’Avella |
Clinical Lung Cancer
|
|
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
|
April 13, 2022
|
PC3I Authors Charu Aggarwal |
Journal for Immunotherapy of Cancer
|
|
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer
|
April 22, 2022
|
PC3I Authors Charu Aggarwal |
Journal of Clinical Oncology
|
|
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
|
May 31, 2022
|
PC3I Authors Charu Aggarwal |
Journal for Immunotherapy of Cancer
|
|
Aumolertinib in EGFR-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease Access?
|
June 9, 2022
|
PC3I Authors Charu Aggarwal |
Journal of Clinical Oncology
|
|
Development of a robust radiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first-line immunotherapy
|
June 15, 2022
|
PC3I Authors Charu Aggarwal |
Scientific Reports
|
|
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
|
August 11, 2022
|
PC3I Authors Charu Aggarwal |
JCO Precision Oncology
|
|
Prevalence of ARID1A Mutations in Cell-Free Circulating Tumor DNA in a Cohort of 71,301 Patients and Association with Driver Co-Alterations
|
September 9, 2022
|
PC3I Authors Charu Aggarwal |
Cancers (Basel)
|
|
Pembrolizumab Administration Frequency, Dose Exposure, and Toxicity: Is Switching Safe?
|
October 3, 2022
|
PC3I Authors Charu Aggarwal |
Journal of Thoracic Oncology
|
|
Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
|
December 1, 2022
|
PC3I Authors Charu Aggarwal |
Clinical Cancer Research
|
|
Use of Erdafitinib in FGFR3-Mutated Recurrent Respiratory Papillomatosis
|
December 1, 2022
|
PC3I Authors Charu Aggarwal |
JCO Precision Oncology
|
|
Adjuvant Atezolizumab Should Be Administered to All Patients With Programmed Death-Ligand 1 Expressing Surgically Resected Stage II to III NSCLC After Chemotherapy: In Favor
|
February 26, 2023
|
PC3I Authors Melina Marmarelis; Charu Aggarwal |
Journal of Thoracic Oncology
|
|
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
|
March 13, 2023
|
PC3I Authors Charu Aggarwal |
Clinical Cancer Research
|
|
Molecular Marker Testing in Curable Non-Small Cell Lung Cancer-Practice Necessarily Precedes Data
|
April 13, 2023
|
PC3I Authors Charu Aggarwal |
JAMA Oncology
|
|
Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System
|
April 19, 2023
|
PC3I Authors Michelle Iocolano; Christopher A. D’Avella; Melina Marmarelis; Charu Aggarwal |
Clinical Lung Cancer
|
|
Re-Evaluating Real-World Evidence in RET Fusion-Positive NSCLC: Are Randomized Clinical Trials Needed?
|
April 22, 2023
|
PC3I Authors Charu Aggarwal; Melina Marmarelis |
Journal of Thoracic Oncology
|
|
Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy
|
May 2, 2023
|
PC3I Authors Charu Aggarwal |
JAMA Network Open
|
|
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer
|
May 15, 2023
|
PC3I Authors Charu Aggarwal; Christopher A. D’Avella; Melina Marmarelis |
The Oncologist
|
